文献速递造血干细胞移植与细胞治疗淋巴瘤

异基因移植后免疫重建延迟增加死亡与慢性GVHD风险

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.
PubMed 文献 · Blood Adv · 2018-01-01

研究纳入157例成人减低强度预处理异基因移植受者,比较68例配合同胞供者外周血移植与89例脐带血移植的免疫重建速度。脐带血受者早期NK细胞少但后期较高,T细胞亚群恢复较慢,细菌和病毒感染更频繁,但供者类型对治疗相关死亡和生存无影响。第28天总CD4+和初始CD4+ T细胞低与感染风险、治疗相关死亡和慢性GVHD增加显著相关。

要点

  • 脐带血移植后6个月至1年T细胞亚群恢复慢于配合同胞供者移植。
  • 第28天CD4+和初始CD4+ T细胞低与感染、治疗相关死亡和慢性GVHD风险增加相关。
  • 供者类型对治疗相关死亡和生存无显著影响。

核心结论

  • 移植后第28天总CD4+ T细胞和初始CD4+ T细胞数量较低与感染风险、治疗相关死亡和慢性GVHD增加显著相关。
  • 具有这些特征的患者可能受益于加强或延长感染监测和预防以及加速免疫重建的策略。

研究设计与样本

  • 评估157例成人减低强度预处理后配合同胞供者外周血移植(n=68)和脐带血移植(n=89)受者的免疫重建速度。

主要发现

  • 第28天脐带血受者自然杀伤(NK)细胞少于配合同胞供者受者,但此后NK细胞数量及其亚群在脐带血受者中较高。
  • 移植后6个月至1年,脐带血受者T细胞亚群恢复较慢,CD3+、CD8+、CD8+初始、CD4+初始、CD4+效应记忆T、调节性T和CD3+CD56+ T细胞数量低于配合同胞供者受者。
  • 第60天至1年,脐带血受者B细胞数量较高。
  • 脐带血受者细菌和病毒感染更频繁,但供者类型对治疗相关死亡或生存无影响。
  • 考虑所有患者第28天,总CD4+ T细胞和初始CD4+ T细胞数量较低与感染风险、治疗相关死亡和慢性GVHD增加显著相关。

临床怎么用

  • 作者认为具有第28天低CD4+ T细胞和低初始CD4+ T细胞特征的患者可能受益于加强或延长感染监测和预防以及加速免疫重建的策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Slow immune reconstitution is a major obstacle to the successful use of allogeneic hematopoietic cell transplantation (allo-HCT). As matched sibling donor (MSD) allo-HCT is regarded as the gold standard, we evaluated the pace of immune reconstitution in 157 adult recipients of reduced-intensity conditioning followed by MSD peripheral blood HCT (n = 68) and compared these to recipients of umbilical cord blood (UCB; n = 89). At day 28, UCB recipients had fewer natural killer (NK) cells than MSD recipients, but thereafter, NK cell numbers (and their subsets) were higher in UCB recipients. During the first 6 months to 1 year after transplant, UCB recipients had slower T-cell subset recovery, with lower numbers of CD3+, CD8+, CD8+ naive, CD4+ naive, CD4+ effector memory T, regulatory T, and CD3+CD56+ T cells than MSD recipients. Notably, B-cell numbers were higher in UCB recipients from day 60 to 1 year. Bacterial and viral infections were more frequent in UCB recipients, yet donor type had no influence on treatment-related mortality or survival. Considering all patients at day 28, lower numbers of total CD4+ T cells and naive CD4+ T cells were significantly associated with increased infection risk, treatment-related mortality, and chronic graft-versus-host disease (GVHD). Patients with these characteristics may benefit from enhanced or prolonged infection surveillance and prophylaxis as well as immune reconstitution-accelerating strategies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bejanyan N, Brunstein CG, Cao Q, et al. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv. 2018. PMID: 29678809. doi:10.1182/bloodadvances.2017014464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。